Effect of Tocilizumab in Adults Hospitalized With COVID-19 With Moderate or Severe Pneumonia

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 1 P.M. (ET), TUESDAY, OCTOBER 20, 2020

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2020.6820?guestAccessKey=14a265c4-49ae-44a2-ac1e-4ed9bc9181f6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102020

 

What The Study Did: This randomized clinical trial assessed whether tocilizumab improves outcomes of patients hospitalized with moderate-to-severe COVID-19 pneumonia compared to usual care.

Authors: Olivier Hermine, M.D., Ph.D., of the Université de Paris, is the corresponding author.

 

(doi:10.1001/jamainternmed.2020.6820)

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.